Natera (HAM:45E) Cyclically Adjusted Revenue per Share: €0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:45E Natera Inc HAM:45E
59 GF Score
Price €274.40
GF Value €179.22
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Natera Cyclically Adjusted Revenue per Share?

Natera HAM:45E +2.62% 59 Cyclically Adjusted Revenue per Share is €0.00 as of Jun. 2026. GuruFocus rates HAM:45E with a GF Score™ of 59/100 and a GF Value™ of €179.22 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Natera's adjusted revenue per share for the three months ended in Jun. 2026 was €4.560. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Natera's average Cyclically Adjusted Revenue Growth Rate was 20.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-21), Natera's current stock price is €274.40. Natera's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €0.00. Natera's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Natera was 33.86. The lowest was 6.12. And the median was 20.37.


Natera  (HAM:45E) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Natera was 33.86. The lowest was 6.12. And the median was 20.37.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Natera Cyclically Adjusted Revenue per Share Related Terms


Natera Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Natera's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Natera Cyclically Adjusted Revenue per Share Chart

Natera Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Natera Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HAM:45E vs : Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Natera's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Natera Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Natera's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Natera's Cyclically Adjusted PS Ratio falls into.


HAM:45E
59GF Score
Natera Inc HAM:45E
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Natera Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Natera's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=4.56/333.9520*333.9520
=4.560

Current CPI (Jun. 2026) = 333.9520.

Natera Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.923 241.428 1.277
201612 0.809 241.432 1.119
201703 0.870 243.801 1.192
201706 0.877 244.955 1.196
201709 0.878 246.819 1.188
201712 0.798 246.524 1.081
201803 0.934 249.554 1.250
201806 0.990 251.989 1.312
201809 0.924 252.439 1.222
201812 0.949 251.233 1.261
201903 0.941 254.202 1.236
201906 0.965 256.143 1.258
201909 1.004 256.759 1.306
201912 0.978 256.974 1.271
202003 1.087 258.115 1.406
202006 0.971 257.797 1.258
202009 1.030 260.280 1.322
202012 1.077 260.474 1.381
202103 1.476 264.877 1.861
202106 1.338 271.696 1.645
202109 1.452 274.310 1.768
202112 1.615 278.802 1.934
202203 1.844 287.504 2.142
202206 1.941 296.311 2.188
202209 2.192 296.808 2.466
202212 1.964 296.797 2.210
202303 2.020 301.836 2.235
202306 2.122 305.109 2.323
202309 2.183 307.789 2.369
202312 2.391 306.746 2.603
202403 2.800 312.332 2.994
202406 3.126 314.175 3.323
202409 3.201 315.301 3.390
202412 3.460 315.605 3.661
202503 3.445 319.799 3.597
202506 3.475 322.561 3.598
202509 3.678 324.800 3.782
202512 4.108 324.054 4.233
202603 4.259 330.213 4.307
202606 4.560 333.952 4.560

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.00 mean?
Natera (HAM:45E) has a Cyclically Adjusted Revenue per Share of €0.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Natera and its competitors.
Is Natera's Cyclically Adjusted Revenue per Share too high?
Natera's current Cyclically Adjusted Revenue per Share is €0.00. Overall, Natera has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Natera's Cyclically Adjusted Revenue per Share compare to ?
Natera's Cyclically Adjusted Revenue per Share of €0.00 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Natera and its competitors. Natera's current Cyclically Adjusted Revenue per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natera stock overvalued right now?
Based on GuruFocus' analysis, Natera (HAM:45E) is currently considered Significantly Overvalued. The stock's GF Value™ is €179.22, compared to a current price of €274.40 — trading 53.1% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.00. Natera's overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Natera (HAM:45E), the current Cyclically Adjusted Revenue per Share is €0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Natera (HAM:45E) Overvalued in 2026?

Based on GuruFocus' analysis, Natera stock appears to be overvalued. The current stock price of €274.40 is trading 53.1% above its estimated GF Value™ of €179.22. GuruFocus considers Natera to be Significantly Overvalued.

Key valuation signals for HAM:45E:

  • Cyclically Adjusted Revenue per Share: €0.00
  • GF Value™: €179.22 vs. price of €274.40 (53.1% above fair value)
  • GF Score™: 59/100 with 6 warning signs

No single metric tells the full story. See the HAM:45E stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Natera Business Description

Comparable Companies
Other Exchanges NTRA:USANTRA:Mexico
Address 13011 McCallen Pass, Building A Suite 100, Austin, TX, USA, 78753
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
59GF Score

Get the complete analysis for HAM:45E

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€274.40
Price
€179.22
GF Value